WARFARIN ANTIPLATELET RECURRENT STROKE STUDY

华法林抗血小板治疗复发性卒中研究

• 批准号: 6121274
• 负责人: L. CREED Pettigrew
• 金额: $ 2.65万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6121274
• 关键词: aspirin; brain disorder chemotherapy; clinical research; drug quality /standard; human morbidity; human subject; human therapy evaluation; platelet aggregation inhibitors; relapse /recurrence; stroke; warfarin

To compare the effectiveness of warfarin versus a medication that inhibits platelet aggregation (aspirin) as post-stroke treatment, analyzing frequency of death, stroke recurrence, and safety over a two-year period.

比较华法林与抑制血小板聚集药物（阿司匹林）作为中风后治疗的有效性，分析两年内的死亡频率、中风复发和安全性。